RxDoctor Payments Data

Theodore Lau, MD

Interventional Cardiology · Tacoma, WANPI 1205986312

Payments from drug & device makers

$4,193in general payments, 2019–2025

Across 37 payments — averaging $113.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$1K
  • Biosense Webster, Inc.$1K
  • Boston Scientific$901
  • Medtronic$293
  • Abiomed$259
  • Livanova USA, Inc.$142
  • plus $206 from 4 others

What the payments were for

  • Travel & lodging$2,19952%
  • Food & beverage$1,99448%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,193 in reported general payments places this provider in the 45th percentile of 125 interventional cardiology providers in Washington.

See all interventional cardiology providers in Washington

Medicare billing

Part B allowed, 2024
$255,910
Medicare patients
1,058
Services billed
2,417

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban378$439,794
XareltoRivaroxaban173$231,398
Repatha SureclickEvolocumab197$192,690
EntrestoSacubitril/Valsartan119$159,907
Praluent PenAlirocumab45$48,613
JardianceEmpagliflozin29$35,102
VascepaIcosapent Ethyl22$18,541
Ezetimibe443$12,823
BrilintaTicagrelor18$11,677
Atorvastatin Calcium903$8,272
Dabigatran EtexilateDabigatran Etexilate Mesylate24$8,064
Repatha PushtronexEvolocumab13$8,021
Ranolazine ErRanolazine78$7,367
Rosuvastatin Calcium441$6,698
Metoprolol Succinate376$5,535

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Esperion Therapeutics, Inc.Nexlizet$125$5,47712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 125 interventional cardiology providers in Washington.

Other interventional cardiology in Tacoma

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →